Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E14.73 EPS (ttm)20.54 Insider Own20.10% Shs Outstand108.82M Perf Week-0.85%
Market Cap32.93B Forward P/E12.66 EPS next Y23.90 Insider Trans-0.07% Shs Float79.40M Perf Month-9.23%
Income2.36B PEG1.84 EPS next Q5.46 Inst Own73.90% Short Float3.34% Perf Quarter-28.06%
Sales6.91B P/S4.76 EPS this Y57.40% Inst Trans1.87% Short Ratio3.31 Perf Half Y-10.29%
Book/sh86.73 P/B3.49 EPS next Y6.38% ROA21.40% Target Price397.60 Perf Year-1.76%
Cash/sh29.70 P/C10.19 EPS next 5Y8.00% ROE29.20% 52W Range291.10 - 442.00 Perf YTD-18.99%
Dividend- P/FCF15.71 EPS past 5Y40.30% ROI24.90% 52W High-31.55% Beta1.11
Dividend %- Quick Ratio4.00 Sales past 5Y26.10% Gross Margin93.40% 52W Low3.94% ATR11.08
Employees7400 Current Ratio4.60 Sales Q/Q13.30% Oper. Margin35.40% RSI (14)27.68 Volatility2.49% 2.95%
OptionableYes Debt/Eq0.08 EPS Q/Q-4.00% Profit Margin35.10% Rel Volume0.91 Prev Close304.94
ShortableYes LT Debt/Eq0.08 EarningsMay 07 BMO Payout0.00% Avg Volume800.77K Price302.57
Recom2.50 SMA20-7.95% SMA50-18.31% SMA200-20.88% Volume726,958 Change-0.78%
May-08-19Reiterated Canaccord Genuity Hold $408 → $353
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-20-19 04:14PM  Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study Zacks
08:45AM  5 Cheap Stocks to Ride Out the Trade War Barrons.com
May-19-19 10:55PM  Edited Transcript of REGN earnings conference call or presentation 7-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-17-19 09:32AM  Moving Average Crossover Alert: Regeneron Pharmaceuticals Zacks
May-16-19 10:44AM  Regeneron Cancer Drug Gives Anxious Investors Hope Barrons.com
09:48AM  Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer MarketWatch
08:20AM  Pfizer's Eczema Candidate Meets All Goals in Phase III Study Zacks
07:00AM  Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
May-15-19 10:49AM  Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates Zacks
May-14-19 09:05AM  Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion Zacks
07:42AM  The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings Benzinga
May-13-19 04:19PM  FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy PR Newswire
02:45PM  FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy PR Newswire
09:27AM  5 Growthy Biotech Stocks to Buy Despite the Scrutiny InvestorPlace
May-10-19 10:21AM  Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates Zacks
May-09-19 01:39PM  Parnassus Endeavor Fund Buys 2 Pharmaceutical Stocks in 1st Quarter GuruFocus.com
May-08-19 09:37AM  Here's the Bad News That Derailed Regeneron's Stock Motley Fool
May-07-19 05:24PM  Regeneron Pharmaceuticals (REGN) Q1 2019 Earnings Call Transcript Motley Fool -6.34%
04:08PM  Regeneron Earnings: Slammed On Costs, Cancer Setback Shares Dive Investor's Business Daily
03:00PM  What's Behind Regeneron's Q1 Revenue and Earnings Misses Motley Fool
01:20PM  Regeneron Stock Could Fall 13% to 52-Week Lows TheStreet.com
01:15PM  Stocks making the biggest moves midday: Beyond Meat, Boeing, Mylan & more CNBC
01:09PM  Regeneron Stock Is Diving Because Earnings Disappointed Barrons.com
12:42PM  Regeneron Declines on First-Quarter Earnings Miss TheStreet.com
11:52AM  Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss InvestorPlace
11:45AM  US STOCKS-Wall Street plunges on heightening U.S.-China trade worries Reuters
10:23AM  US STOCKS-Wall Street declines on U.S.-China trade tensions Reuters
09:02AM  Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission GlobeNewswire
08:59AM  Dupixent® (dupilumab) Approved for Severe Asthma by European Commission PR Newswire
08:36AM  US STOCKS-Wall Street set for lower open on trade jitters Reuters
08:19AM  Regeneron stock down 4.1% after earnings and revenue miss MarketWatch
08:00AM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
07:59AM  Stocks making the biggest moves premarket: Ferrari, Boeing, PepsiCo, Mosaic, Hertz, AIG & more CNBC
07:45AM  Regeneron (REGN) Misses Q1 Earnings and Revenue Estimates Zacks
06:39AM  Regeneron: 1Q Earnings Snapshot Associated Press
06:30AM  Regeneron Reports First Quarter 2019 Financial and Operating Results PR Newswire
02:38AM  Regeneron Pharma Earnings, Revenue Miss in Q1 Investing.com
May-06-19 03:33PM  Regeneron Pharmaceuticals Expected to Earn $5.48 a Share TheStreet.com
12:12PM  Brief Commentary On Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Simply Wall St.
11:50AM  bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y Zacks
May-04-19 04:56PM  The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs Benzinga
May-02-19 04:57PM  Regeneron (REGN) to Report Q1 Earnings: What's in Store? Zacks
10:00AM  Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1 Zacks
09:16AM  Can Alnylam Pharmaceuticals Stock Start Climbing Again? Motley Fool
May-01-19 11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
Apr-30-19 03:18PM  5 Biotech Stocks for a Long-Lived Portfolio InvestorPlace
10:32AM  Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-29-19 04:01PM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
Apr-26-19 08:09PM  U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug Reuters
07:40PM  U.S. FDA approves expanded label for Regeneron's cholesterol drug Reuters
07:22PM  Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization GlobeNewswire
07:19PM  FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization PR Newswire
11:17AM  CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma GlobeNewswire
11:15AM  CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
09:29AM  Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales Zacks
Apr-24-19 03:42PM  Why Investors Should Buy the Dip in MRK Stock InvestorPlace
Apr-22-19 06:59PM  How to Invest at Every Age: Cramer's 'Mad Money' Recap (Monday 4/22/19) TheStreet.com
01:54PM  This Is Why You Shouldnt Count Regeneron Stock Out InvestorPlace
08:30AM  A Bullish Play on Netflix TheStreet.com
Apr-18-19 03:17PM  Health-care drama has now spread to biopharma stocks MarketWatch
Apr-16-19 07:13PM  Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran Zacks
11:46AM  Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Simply Wall St.
10:57AM  Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA Zacks
Apr-15-19 04:49PM  Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran Zacks
08:30AM  Stalking an Entry in Regeneron Pharmaceuticals TheStreet.com
Apr-12-19 09:42AM  5 things to know about Hookipa Pharma ahead of its IPO MarketWatch
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Apr-10-19 09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
Apr-09-19 09:03AM  Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics Zacks
Apr-08-19 04:01PM  Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019 PR Newswire
01:55PM  Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics Benzinga
11:13AM  Regeneron forays into gene-silencing therapies with Alnylam tie-up Reuters
09:10AM  Alnylam trades partner Sanofi for Regeneron in $800M deal American City Business Journals
07:11AM  Alnylam, Regeneron to partner for RNAi treatments Reuters
07:00AM  Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases PR Newswire
07:00AM  Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases Business Wire
Apr-04-19 10:36AM  Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up Zacks
Apr-03-19 10:00AM  Allergan's AMD Drug Lowers Inflammation in Phase III Study Zacks
Apr-02-19 10:51AM  Inovio Closes Enrollment in Brain Cancer Study Before Time Zacks
Mar-28-19 08:20AM  Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy? Insider Monkey
Mar-27-19 10:52AM  Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Financial Strength Analysis Simply Wall St.
Mar-25-19 04:26PM  Peninsula biotech lines up chance to crack the peanut allergy nut American City Business Journals
07:40AM  Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-24-19 09:00AM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Mar-21-19 09:46AM  Biogen shares tank nearly 30% after pulling key Alzheimers drug trial Yahoo Finance
Mar-20-19 07:07AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Mar-18-19 06:59PM  Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent Zacks
11:28AM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks
11:15AM  Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop Bloomberg
Mar-15-19 04:02PM  Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease GlobeNewswire
03:15PM  Try These 3 Steps To Compound Your Profits In The Best Growth Stocks Investor's Business Daily
Mar-13-19 10:55AM  10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run Zacks
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
10:03AM  Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down Zacks
07:00AM  Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19 PR Newswire
05:04AM  Inovio Pharmaceuticals (INO) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-12-19 09:56PM  Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem PR Newswire
03:22PM  Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion Zacks
11:36AM  FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents PR Newswire
Mar-11-19 04:32PM  Regeneron/Sanofi wins U.S. approval for expanded use of skin drug Reuters
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorMay 15Sale305.931,000305,93011,323May 15 08:42 PM
STAHL NEILEVP Research and DevelopmentMay 14Sale305.749,8533,012,48322,450May 15 04:02 PM
STAHL NEILEVP Research and DevelopmentMay 13Option Exercise52.0325,0001,300,75047,450May 15 04:02 PM
Fenimore Christopher R.VP ControllerApr 18Option Exercise21.253507,4387,446Apr 18 07:04 PM
SCHLEIFER LEONARD SPresident & CEOMar 21Option Exercise21.251002,125424,062Mar 22 04:03 PM
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 13Option Exercise16.80244,0484,100,006167,185Dec 17 04:02 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise16.80312,5005,250,000488,014Dec 14 04:19 PM
VAGELOS P ROYChairman of the BoardDec 12Sale382.3262,2942,304Dec 14 04:49 PM
GOLDSTEIN JOSEPH LDirectorSep 28Option Exercise273.67709194,03212,709Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 28Sale410.00709290,69012,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Option Exercise273.672,000547,3402,000Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 27Option Exercise273.672,000547,34014,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 27Sale400.002,000800,00012,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Sale392.262,000784,5240Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 24Option Exercise273.672,000547,34013,000Sep 25 04:05 PM
GOLDSTEIN JOSEPH LDirectorSep 24Sale388.652,000777,29012,000Sep 25 04:05 PM
Fenimore Christopher R.VP ControllerAug 30Option Exercise21.25501,063200Aug 31 04:02 PM
BROWN MICHAEL SDirectorAug 22Option Exercise177.821,500266,7301,500Aug 23 04:01 PM
BROWN MICHAEL SDirectorAug 22Sale380.491,500570,7350Aug 23 04:01 PM
VAGELOS P ROYChairman of the BoardAug 20Option Exercise21.252104,463400,057Aug 21 04:55 PM
GOLDSTEIN JOSEPH LDirectorAug 02Option Exercise57.112,000114,22014,000Aug 03 04:03 PM
GOLDSTEIN JOSEPH LDirectorAug 02Sale380.002,000760,00012,000Aug 03 04:03 PM
VAGELOS P ROYChairman of the BoardJul 10Sale367.2274,67027,420,277399,847Jul 11 04:04 PM
VAGELOS P ROYChairman of the BoardJul 09Option Exercise16.80153,2742,575,003553,121Jul 11 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Sale370.002,000740,00012,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Sale360.002,000720,00012,000Jul 09 04:04 PM
VAGELOS P ROYChairman of the BoardJun 21Sale327.8774,71024,495,410399,847Jun 22 04:03 PM
VAGELOS P ROYChairman of the BoardJun 20Option Exercise16.80153,2742,575,003553,121Jun 22 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
open in yahoo | open in reuters | open in google